Sarepta Therapeutics
SRPT
306 hedge funds and large institutions have $6.08B invested in Sarepta Therapeutics in 2021 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 114 increasing their positions, 102 reducing their positions, and 64 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
21% more capital invested
Capital invested by funds: $5.04B → $6.08B (+$1.04B)
12% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 102
1.09% more ownership
Funds ownership: 81.32% → 82.41% (+1.1%)
5% more call options, than puts
Call options by funds: $158M | Put options by funds: $150M
7% less funds holding
Funds holding: 330 → 306 (-24)
31% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$110M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$43.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$38.8M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$38.5M |
| 5 |
Holocene Advisors
New York
|
+$29.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$170M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$39.2M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$31.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.2M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$13.3M |
SRPT Hedge Fund Activity: Q3 2021 in Review
306 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2021, worth a combined $6.08B — up 21% from $5.04B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of SRPT and 44 opened new positions — a net loss of 20 holders — while 102 trimmed existing stakes and 114 added.
The largest buyer was Point72 Asset Management, adding an estimated $110M. The largest seller was Capital Research Global Investors, cutting an estimated $170M.
- 306 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2021, down from 330 in Q2 2021.
- Funds reported $6.08B of Sarepta Therapeutics stock for Q3 2021, up 21% quarter-over-quarter.
- 44 funds opened new Sarepta Therapeutics positions in Q3 2021 and 64 closed out, a net change of -20 holders.
- The largest Sarepta Therapeutics buyer in Q3 2021 was Point72 Asset Management, an estimated $110M added.
- The largest Sarepta Therapeutics seller in Q3 2021 was Capital Research Global Investors, an estimated $170M sold.
Based on aggregated 13F filings for Q3 2021.